Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03083353
EARLY_PHASE1

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Sponsor: Jasper A. Smits

View on ClinicalTrials.gov

Summary

The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

78

Start Date

2020-01-22

Completion Date

2023-06-14

Last Updated

2026-06-15

Healthy Volunteers

Yes

Interventions

DRUG

Isradipine

Isradipine will be administered 90 minutes prior to the initiation of cue exposure.

BEHAVIORAL

Cue Exposure

Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.

Locations (1)

University of Texas at Austin

Austin, Texas, United States